Medical bodies back ABPI Code changes
March 4, 2011Medical Communications ABPI, ABPI Code of Practice, Code of Practice, GMC, INFORCE, Nottingham, Royal College of Physicians, industry relations, trust
Leading medical organisations have signed a joint declaration backing the forthcoming changes to UK pharma’s self-regulatory Code of Practice. In …
NICE rejects Lucentis for diabetic oedema
March 4, 2011Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab
NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
Digital Pharma: European doctors’ communities collaborate
March 3, 2011Medical Communications, Sales and Marketing Coliquio, Digital Pharma blog, Doctors.net.uk, online doctors communities
Two of Europe’s leading medical professional communities have signed a strategic alliance that will see them collaborate on multi-market digital …
Jim McDermott to lead Quintiles Market Intelligence
March 3, 2011Sales and Marketing Jim McDermott, Quintiles, appointment, sales and marketing
Quintiles has appointed Jim McDermott as managing director of the Market Intelligence practice within its Consulting group. The practice provides …
Universities to ‘pick up pharma’s R&D mantle’ after Pfizer closure
March 3, 2011Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee, UK research, UK science, job cuts
Science in the UK will have to focus on contractually-based research in the future as pharma’s R&D presence in the …
GSK to reimburse tuition fees for UK trainees
March 3, 2011Business Services, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment
GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012. Each year, GSK recruits between …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
RNA interference – still the great white hope?
March 3, 2011Manufacturing and Production, Research and Development RNA interference, rnai
The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …
NHS competition plans provide focus for dissent
March 3, 2011Health and Social Care Bill, NHS, NHS reforms
Confusion and controversy surround the government plans to introduce greater levels of competition into the NHS, with many stakeholder groups …
FDA knocks back Merck KGaA’s oral MS drug
March 2, 2011Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs
US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …
UCB teams up with Harvard for CNS research
March 2, 2011Research and Development CNS, Harvard, UCB, academia, academic research, immunology
UCB has signed a new research collaboration with Harvard University that will focus on central nervous system and immunology therapies. …
Boehringer’s Kay O’Hagan moves to Brecon
March 2, 2011Manufacturing and Production, Research and Development Brecon, Kay O'Hagan, appointment, manufacturing and production, research and development
Kay O’Hagan has joined commercial packaging and clinical trials supply services company Brecon Pharmaceuticals as director of quality assurance and …
Avastin’s breast cancer use to continue in Europe
March 2, 2011Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel
Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …
GlaxoSmithKline seeks alliances with ‘academic superstars’
March 2, 2011Research and Development GSK, GlaxoSmithKline, Pentraxin Therapeutics, academia, al Free and University College Medical School, universities
GlaxoSmithKline has unveiled a partnership with a ‘superstar academic’, as part of a new strategy which it believes will help …
Daiichi Sankyo gains rights to potential blockbuster cancer drug
March 2, 2011Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine
Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
Samsung forges biosimilar venture with Quintiles
March 2, 2011Manufacturing and Production Quintiles, Samsung, biosimilar production, biosimilars, pharma production
South Korean electronics giant Samsung has formed a joint venture with Quintiles with the objective of breaking into the market …
Fujifilm buys into bio with Merck acquisitions
March 2, 2011Manufacturing and Production Biomanufacturing, Fujifilm, Merck, Merck & Co, Merck/MSD Biomanufacturing Network, contract manufacturing
Japanese photography and imaging company Fujifilm continued its diversification into other sectors with the acquisition of the Merck/MSD Biomanufacturing Network, …
Bayer goes for pharma growth
March 1, 2011Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto
While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …
Pfizer drops 15 pipeline projects
March 1, 2011Research and Development Lyrica, Pfizer, Pfizer R&D, Pfizer product pipeline, Pfizer research, inotuzumab, pregabalin
Pfizer has again slimmed down its product pipeline as the US giant looks to cut R&D spending and sharpen its …
LEO Pharma Selects Veeva CRM for Pan-European Deployments
March 1, 2011Sales and Marketing veeva
BARCELONA, SPAIN — 1 March, 2011 – LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
